Mary-Ann Bjornsti, Ph.D., is Chair of the Department of Pharmacology and Toxicology at UAB, and holds the Newman H. Waters Chair of Clinical Pharmacology. She also serves as co-Leader of the Cancer Cell Biology Program and Associate Director for Translational Research in the UAB Comprehensive Cancer Center. She received her Ph.D. from the University of Minnesota in Genetics, followed by a Fogarty Fellowship at the Biozentrum in Basel Switzerland, and post-doctoral training at Harvard University ...
Mary-Ann Bjornsti, Ph.D., is Chair of the Department of Pharmacology and Toxicology at UAB, and holds the Newman H. Waters Chair of Clinical Pharmacology. She also serves as co-Leader of the Cancer Cell Biology Program and Associate Director for Translational Research in the UAB Comprehensive Cancer Center. She received her Ph.D. from the University of Minnesota in Genetics, followed by a Fogarty Fellowship at the Biozentrum in Basel Switzerland, and post-doctoral training at Harvard University ...
Dr. Barnes was trained in Chemistry and Biochemistry in the UK. He joined UAB in 1977 and pursued research on bile acids and latterly polyphenols, particularly soy isoflavones. He was promoted to Associate Professor (with tenure) in 1985 and Full Professor in 1994. He has received NIH support from several areas to pursue the conjugation of bile acids, the chemistry, biochemistry and physiology of polyphenols, the underlying chemistry of lens cataracts and the use of omics approaches in biomedica...
Dr. Standaert was named the John N. Whitaker Professor & Chair of Neurology in 2012. Prior to that, he was appointed the John T. and Juanelle D. Strain Endowed Chair by the Board of Trustees of the University of Alabama system, which he held for five years. He received his M.D. and Ph.D. degrees from Washington University in St. Louis in medicine and pharmacology in 1988. He completed a one-year internship in medicine at Jewish Hospital of St. Louis in 1989 and a three-year neurology residency i...
Dr. Mobley is considered an expert in proteomics by his peers, and as director of the Mass Spectrometry/Proteomics Shared Facility, continues to focus on clinical and translational proteomics applications, which include statistical analysis of high density 'omics driven data sets, and the use of systems biology applications to uncover biologically relevant pathways. He has nearly 30 years experience in academia and industry, and mass spectrometry has been a intricate part of his work experience ...
Lewis Shi received his MD in preventive medicine, MS in toxicology, and PhD in neurotoxicology. Upon graduation, he worked as a postdoctoral scholar at University of Wisconsin-Madison where he identified a novel role of the aryl hydrocarbon receptor (AhR) signaling in innate immune response against Listeria monocytogenes infection. He then joined St. Jude Children’s Research Hospital where he was among the first to show that the HIF-1a-glycolysis pathway functions as a metabolic checkpoint in re...
Dr. Limdi is a clinical pharmacist and epidemiologist with significant expertise in pharmacogenomics and pharmacoepidemiology, from research and discovery to its application and implementation in clinical practice. Her research portfolio encompasses studies with both observational and a clinical trial designs and is focused on understanding the multiple factors that influence drug efficacy and safety, specifically anticoagulant and antiplatelet response. An established investigator in the field ...
Dr. Rui-Ming Liu received her M.D. and PhD (in Toxicology) degrees from Tongji Medical University, Wuhan, China. She is an American Board of Toxicology certified Toxicologist. Dr. Liu joined the UAB School of Public Health in 1999 as an Assistant Professor and was promoted to Associate Professor in 2005. In 2014, Dr. Liu was promoted to Professor with tenure and moved from School of Public Health to School of Medicine, Pulmonary, Allergy, and Critical Care Division.
My research program studies how genetic, environmental, and/or lifestyle factors influence the initiation, progression, and severity of liver and cardiovascular diseases using experimental animal model systems. Our goal is to identify molecular factors and mechanisms that enhance alcohol and obesity-related fatty liver disease. Principal areas are focused on understanding how disruption in lipid and glycogen metabolism, redox signaling, and mitochondrial bioenergetic function contribute to patho...
